Fortress Biotech Third-Quarter Total Net Revenue Rises About 9 Percent to 19.2 Million Dollars: Cash of 152.2 Million Dollars and a Net Loss of 7.9 Million Dollars
Fortress Biotech, an innovative biopharmaceutical company, announced financial results and recent corporate highlights for the third quarter ended September 30, 2026 in Miami on November 13, 2026.
Fortress' consolidated net revenue totaled 19.2 million dollars for the third quarter of 2026, of which 18.9 million dollars was generated from marketed dermatology products. This compares with consolidated net revenue of 17.6 million dollars for the third quarter of 2025, of which 17.0 million dollars came from marketed dermatology products. Journey Medical reported net product revenues of 18.9 million dollars for the quarter, against 17.0 million dollars a year earlier.
Consolidated net loss attributable to common stockholders was 7.9 million dollars, or 0.23 dollars per share basic and diluted, for the third quarter of 2026, compared with net income attributable to common stockholders of 3.7 million dollars, or 0.13 dollars per share basic and 0.11 dollars diluted, a year earlier.
As of September 30, 2026, Fortress' consolidated cash and cash equivalents totaled 152.2 million dollars, compared with 79.4 million dollars as of December 31, 2025. Net revenue for the first nine months of 2026 was 53.9 million dollars, against 47.2 million dollars a year earlier, including product revenue, net of 52.7 million dollars.
Fortress focuses on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. Journey Medical is the main operating business behind its marketed dermatology products.
Source: Fortress Biotech
Published by GSM · USA (original Chinese edition)
Photo: 图：神经元显微影像（Fortress Biotech相关资料图）。Madalena Simões-Abade，CC BY-SA 4.0，Wikimedia Commons。 / Photo: 神经元显微影像. Madalena Simões-Abade, CC BY-SA 4.0, via Wikimedia Commons.
British Insurer Aviva Reports Its Third Quarter 2026 Trading Update: General Insurance Premiums of 11.8 Billion Pounds, Up 19 Percent, a Combined Operating Ratio of 93.8 Percent and a Solvency II Cover Ratio of 179 Percent2026-11-14
Questerre Third-Quarter Production Averages 4,634 Barrels of Oil Equivalent per Day: Petroleum and Natural Gas Revenue of 50.8 Million Canadian Dollars and a Net Loss of 27.6 Million Canadian Dollars as the PX Energy Turnaround Finishes on Schedule, Released November 122026-11-14